A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM)
- Determine the overall response rate in patients with newly diagnosed stage I, II, or
III multiple myeloma treated with vincristine, doxorubicin, dexamethasone, and low-dose
- Determine the ability to collect peripheral blood stem cells in patients after
treatment with this regimen.
OUTLINE: This is an open-label, nonrandomized study.
Patients receive vincristine IV and doxorubicin IV continuously on days 1-4 and oral
dexamethasone on days 1-4, 9-12, and 17-20. Patients also receive low-dose oral thalidomide
daily on days 1-28. Treatment repeats every 4 weeks for 4-6 courses in the absence of
Patients are followed until disease progression or bone marrow transplantation.
PROJECTED ACCRUAL: Approximately 17-37 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
United States: Federal Government
|Roswell Park Cancer Institute||Buffalo, New York 14263|